NCT02084953View on ClinicalTrials.gov

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Hepatitis C
Interventions
DRUG

BMS-791325

DRUG

Moxifloxacin

DRUG

Placebo matching BMS-791325

Trial Locations (1)

78744

Ppd Development, Llc, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY